105 related articles for article (PubMed ID: 28728871)
1. Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis.
Tang H; Wu W; Fu S; Zhai S; Song Y; Han J
J Am Acad Dermatol; 2017 Sep; 77(3):480-488.e9. PubMed ID: 28728871
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Lian Y; Yin H; Pollak MN; Carrier S; Platt RW; Suissa S; Azoulay L
Eur Urol; 2016 Nov; 70(5):808-815. PubMed ID: 27178449
[TBL] [Abstract][Full Text] [Related]
3. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
4. Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis.
Feng S; Zhou L; Liu Q; He Q; Liao B; Wei X; Li H; Wang K; Zhu Y
Medicine (Baltimore); 2018 Jan; 97(3):e9601. PubMed ID: 29504984
[TBL] [Abstract][Full Text] [Related]
5. Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review.
Wang J; Shen Y; Wang J; Xue Y; Liao L; Thapa S; Ji K
Oncotarget; 2017 Jul; 8(28):46461-46467. PubMed ID: 28515348
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.
Matthews A; Langan SM; Douglas IJ; Smeeth L; Bhaskaran K
PLoS Med; 2016 Jun; 13(6):e1002037. PubMed ID: 27299522
[TBL] [Abstract][Full Text] [Related]
7. Association between phosphodiesterase type 5 inhibitors use and risk of melanoma: a meta-analysis.
Deng T; Duan X; Liu B; Lan Y; Cai C; Zhang T; Zhu W; Mai Z; Wu W; Zeng G
Neoplasma; 2018; 65(2):216-221. PubMed ID: 29534582
[TBL] [Abstract][Full Text] [Related]
8. Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-αIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence.
Nardone B; Orrell KA; Vakharia PP; West DP
Expert Opin Drug Saf; 2018 Feb; 17(2):139-147. PubMed ID: 29103328
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the history of PDE5-inhibitors assumption and melanoma: a systematic review.
Cilio S; Briatico G; Brancaccio G; Capone F; Ferro M; Imbimbo C; Salonia A; Argenziano G; Crocetto F
J Basic Clin Physiol Pharmacol; 2023 Nov; 34(6):691-697. PubMed ID: 37982667
[TBL] [Abstract][Full Text] [Related]
10. [Sildenafil and increase in melanoma risk].
Saillen E
Rev Med Suisse; 2014 Jun; 10(433):1268-9. PubMed ID: 25004777
[No Abstract] [Full Text] [Related]
11. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis.
Gandini S; Palli D; Spadola G; Bendinelli B; Cocorocchio E; Stanganelli I; Miligi L; Masala G; Caini S
Crit Rev Oncol Hematol; 2018 Feb; 122():1-9. PubMed ID: 29458778
[TBL] [Abstract][Full Text] [Related]
12. Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans.
Christie A; Vera PL; Higgins M; Kumar S; Lane M; Preston D
Urology; 2019 Apr; 126():116-120. PubMed ID: 30735744
[TBL] [Abstract][Full Text] [Related]
13. Non-genetic risk factors for cutaneous melanoma and keratinocyte skin cancers: An umbrella review of meta-analyses.
Belbasis L; Stefanaki I; Stratigos AJ; Evangelou E
J Dermatol Sci; 2016 Dec; 84(3):330-339. PubMed ID: 27663092
[TBL] [Abstract][Full Text] [Related]
14. No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma.
Wang JZ; Le S; Alexanian C; Boddu S; Merleev A; Marusina A; Maverakis E
World J Mens Health; 2019 Sep; 37(3):313-321. PubMed ID: 30350485
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis.
Tang H; Shi W; Song Y; Han J
J Am Acad Dermatol; 2019 Feb; 80(2):500-507.e10. PubMed ID: 30130598
[TBL] [Abstract][Full Text] [Related]
16. Associations of thiazide use with skin cancers: a systematic review and meta-analysis.
Shao SC; Lai CC; Chen YH; Lai EC; Hung MJ; Chi CC
BMC Med; 2022 Jul; 20(1):228. PubMed ID: 35794547
[TBL] [Abstract][Full Text] [Related]
17. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Seftel AD
J Urol; 2016 Mar; 195(3):713. PubMed ID: 26887740
[No Abstract] [Full Text] [Related]
18. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Penson DF
J Urol; 2015 Dec; 194(6):1710-1. PubMed ID: 26582698
[No Abstract] [Full Text] [Related]
19. [Erectile dysfunction, PDE5A inhibitors and melanoma].
Schmutz JL
Ann Dermatol Venereol; 2015 Dec; 142(12):800-1. PubMed ID: 26293983
[No Abstract] [Full Text] [Related]
20. Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Tasian GE; Cooperberg MR
Eur Urol; 2016 Feb; 69(2):374-5. PubMed ID: 26758522
[No Abstract] [Full Text] [Related]
[Next] [New Search]
